|
|||||
|
|
| 重组人白介素-11治疗化疗所致血小板减少症的应用分析 | |
| 引用本文： | 黎苏,霍虹,崔红霞,刘广宣. 重组人白介素-11治疗化疗所致血小板减少症的应用分析[J]. 中国医院药学杂志, 2018, 38(14): 1530-1533,1544. DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.14.19 |
| 作者姓名： | 黎苏 霍虹 崔红霞 刘广宣 |
| 作者单位： | 1. 中国医科大学肿瘤医院 辽宁省肿瘤医院 药学部, 辽宁 沈阳 110042;2. 中国医科大学药学院药剂教研室, 辽宁 沈阳 110122 |
| 摘 要： | 目的：调查某院恶性肿瘤化疗患者使用重组人白介素-11（rhIL-11）的状况，评价使用rhIL-11的规范性。方法：对某院2016年1月-2017年1月期间接受化疗并且使用过rhIL-11的204例患者用药情况进行回顾性分析，记录患者的个人信息、化疗方案及使用rhIL-11的情况，评价使用合理性。结果：从用药指征、剂量、疗程、停药指征及用药禁忌等方面综合评价，204例患者中52例应用rhlL-11与说明书或专家共识推荐用法完全相符。结论：目前某院rhIL-11的临床应用与说明书及专家共识存在较大差异，临床医师应更加规范的使用rhIL-11。 |
| 关 键 词： | 重组人白介素-11 化疗所致血小板减少症 合理性评价 |
| 收稿时间： | 2017-11-24 |
The application analysis of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia |
|
| LI Su,HUO Hong,CUI Hong-xia,LIU Guang-xuan. The application analysis of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia[J]. Chinese Journal of Hospital Pharmacy, 2018, 38(14): 1530-1533,1544. DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.14.19 | |
| Authors: | LI Su HUO Hong CUI Hong-xia LIU Guang-xuan |
| Affiliation: | 1. Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Liaoning Shenyang 110042, China;2. Department of Pharmaceutics, School of Pharmacy, China Medical University, Liaoning Shenyang 110122, China |
| Abstract: | OBJECTIVE To investigate the clinical application of recombinant human interleukin-11 (rhIL-11) in cancer patients with chemotherapy in our hospital,and standardize the evaluation of rhIL-11 use.METHODS In our hospital from January 2016 to January 2017,application of rhIL-11 for 204 patients was analyzed retrospectively.Normal information,disease related information,chemotherapy and rhIL-11 used in patients were recorded to evaluate the rationality of rhIL-11.RESULTS Comprehensive evaluation was made on the medicinal indication,dosages,course of treatment,indications for withdrawal and contraindications of drugs for the patient.In 204 cases,52 cases of rhlL-11 use were consistent with the instructions or consensus.CONCLUSION In this hospital,there is a big difference in clinical application between instructions and expert consensus.The clinicians should standardize the use of rhIL-11. |
| Keywords: | recombinant human interleukin-11 chemotherapy-induced thrombocytopenia rationality evaluation |
| 点击此处可从《中国医院药学杂志》浏览原始摘要信息 | |
| 点击此处可从《中国医院药学杂志》下载免费的PDF全文 | |